Background Patients with multiple sclerosis who experience disease breakthrough often switch disease-modifying therapy (DMT). Objective To compare treatment effectiveness of switch to highly effective DMT (heDMT) with switch to moderately effective DMT (meDMT) for patients who switch due to disease breakthrough defined as at least one relapse within 12 months of their treatment switch. Methods We retrieved data from The Danish Multiple Sclerosis Registry on all relapsing-remitting MS patients with expanded disability status scale (EDSS) less than 6 who experienced disease breakthrough. We used propensity score matching to compare annualized relapse rates (ARRs), time to first confirmed relapse, time to first confirmed EDSS worsening and time to first confirmed EDSS improvement. Members of the Danish Multiple Sclerosis Group are given in the "Acknowledgements".
Introduction
The disease course of multiple sclerosis (MS) is usually relapsing-remitting, with acute exacerbations followed by full or partial remission of symptoms. Incomplete remission of relapse symptoms can lead to long-lasting neurological deficits. In addition, the so-called silent lesions in the brain and spinal cord may cause permanent disability even in the absence of relapses. Several disease-modifying therapies (DMT) have been approved for the treatment of relapsingremitting MS (RRMS) [1, 2] . The earliest approved therapies [interferon beta (INFβ) and glatiramer acetate (GA)] for RRMS reduced the relapse rate by approximately 30% compared with placebo [3] [4] [5] [6] , teriflunomide and dimethyl fumarate with 31-36% and 44-52%, respectively [7] [8] [9] [10] , whilst the highly effective therapies (heDMT) reduced relapse rates up to 68% compared with placebo [11] [12] [13] . Only fingolimod and alemtuzumab were compared with a moderately effective DMT (meDMT) in a randomized controlled setting as natalizumab was studied as an add-on therapy to INFβ [14] [15] [16] [17] . However, the superior effect of these heDMTs may be associated with an increased risk of serious adverse events. In Denmark, the perceived unfavorable risk-benefit profiles of the currently approved heDMTs (also called second-line treatment: fingolimod, natalizumab, alemtuzumab, cladribine and ocrelizumab) are the reason Sclerosis Registry (DMSR). The records in the DMSR include all patients treated with DMTs, as required by Danish regulators. Patients were included between August 16, 1998 (when all injectables were approved in Denmark) and October 21, 2015 (date of data extraction). Inclusion criteria were prior treatment with no more than one meDMT approved for treatment of RRMS and a subsequent disease breakthrough-induced treatment switch. Other criteria were 18 years of age or more at baseline, baseline EDSS below 6.0, no missing baseline data and a treatment discontinuation gap of less than 180 days (Fig. 1) . The inclusion criterion disease breakthrough was defined as the occurrence of at least one relapse within 1 year of treatment switch or if the treating physician recorded the reason for switching therapy as "treatment failure". The cohort was divided in an meDMT group (switching from one meDMT to another) and an heDMT group (escalating from an meDMT to an heDMT). No patients in Denmark switched directly from their first prescribed meDMT to alemtuzumab. Patients switching to an off-label DMT (e.g., rituximab) and patients treated with an DMT associated with progressive MS (methotrexate, treosulphan and mitoxantrone) were excluded. Clinical visits without a corresponding EDSS record were also excluded. Start of follow-up was defined as the first day of treatment after changing therapy. Patients who did not reach an outcome were censored at switch between heDMT and meDMT, last recorded visit, death or date of data extraction, whichever occurred first. Withinclass switches were not censored. All visits occurring with an interval longer than 3 years after the preceding visit were excluded (2.5% of visits).
Outcome measures
The primary outcome was annualized relapse rate (ARR) and was calculated as the average number of relapses per year during follow-up. The difference in ARR was expressed as relapse rate ratio comparing patients who escalated to an heDMT with patients who switched to an meDMT. Secondary outcomes were time to first relapse, time to first 3-month confirmed EDSS worsening, time to first 3-month confirmed EDSS improvement, time to recurrent relapses and time to recurrent EDSS worsening. An EDSS worsening was defined as a 1.5-point increase if baseline EDSS was 0; 1.0-point increase if baseline EDSS was between 1.0 and 5.5; and 0.5-point increase if baseline EDSS was more than 5.5.
Statistical analyses
We used propensity score matching to balance the two groups. Age at baseline, sex, prior DMT, EDSS at baseline, disease duration from onset to baseline and number of relapses 12 months prior to baseline were included as independent variables in the multivariable logistic regression model used to estimate the propensity scores. EDSS at baseline was classified into five categories ( Table 2 ). All patients had an EDSS record in relation to their treatment start. Patients in the meDMT and heDMT groups were then matched in 1:1 ratio using the nearest neighbor procedure with a caliper of 0.01 and without replacement. The ARR in each study group was compared with a negative binomial regression model taking the paired structure of the data into account. We used Kaplan-Meier estimation to illustrate time from baseline to first relapse, time to first confirmed EDSS worsening and time to first confirmed EDSS improvement. Cox proportional hazards models were used to compare hazard rates for time to first relapse, time to first confirmed EDSS worsening and time to first confirmed EDSS improvement. We used an Andersen-Gill model to compare time to recurrent relapses and time to recurrent EDSS worsening. Proportional hazards were assessed in each model using cumulative martingale residuals. We did not consider death as a competing risk due to the small number of deaths during follow-up; instead, we handled these deaths as standard censorings. We conducted several sensitivity analyses to increase robustness of our results. We changed the caliper in the matching procedure to 0.1, changed the inclusion criteria to EDSS less than 4 at baseline and restricted the study population to patients with a recorded relapse within 6 months of baseline. Moreover, we repeated the analyses with heDMT defined as natalizumab or fingolimod, respectively. Moderate effective DMT Highly effective DMT
Results
Of the patients, 743 escalated to an heDMT and 542 switched to an meDMT and were eligible for inclusion in the study (Fig. 1) . Baseline demographic and clinical characteristics are shown in Table 1 . High-level EDSS and male sex were the strongest predictors of switch to heDMT, while treatment with INFβ-1A 22 µg intramuscularly or INFβ-1B compared with other DMTs predicted switch to an meDMT. Output from the logistic regression is available in the appendix (supplemental Table 1 ) and the EDSS categories are shown in Table 2 . After propensity score matching, the study population consisted of 404 patients in each group, further excluding 477 patients. Baseline variables used in the propensity score were well-balanced by the matching procedure, with all variables having a standardized difference less than 0.1 (Fig. 2) . The majority of patients were included based on a registered relapse within 12 months prior to their treatment switch. Only 6.3% of patients were included exclusively as their switch was labeled as "treatment failure"-4.1% in the heDMT group and 2.2% in the meDMT group. Death was a rare reason for censoring with only six patients (0.7%) dying within one year from their last visit making death negligible as a competing risk. The median follow-up time was 3.2 years [interquartile range (IQR) 1.7-5.9]. Follow-up was comparable between groups: 3.1 years (IQR 1.7-5.9) and 3.3 years (IQR 1.6-6.0) for patients changing treatment to meDMT and heDMT, respectively. The mean number of visits per year during follow-up was also similar with 2.48 visits per year in the heDMT group and 2.52 visits per year in the meDMT group.
Primary and secondary outcomes
The post-switch ARR for patients escalating to an heDMT was 0.22 (95% CI 0.19-0.27), whereas the post-switch ARR for patients switching to another meDMT was 0.32 (95% CI 0.28-0.37), corresponding to a relative reduction of 30% [relapse rate ratio 0.70 (95% CI 0.56-0.86; p = 0.001)]. As illustrated in the Kaplan-Meier curve, patients who escalated to an heDMT had a larger probability of remaining relapse-free compared with the group who switched to another meDMT (log-rank test p < 0.001) (Fig. 3a) . Patients who escalated to an heDMT showed a 35% reduced hazard rate of first relapse (HR 0.65; 95% CI 0.50-0.76; p < 0.001), which was also seen in the Andersen-Gill analysis (HR 0 Fig. 3b , c. Log-rank tests for EDSS worsening and EDSS improvement were p = 0.13 and 0.05, respectively. All results are shown in Table 3 .
Sensitivity analyses
The results of the sensitivity analyses are shown in Table 4 . First, we increased the caliper in the matching procedure to 0.1. This resulted in the larger matched sample of 836 patients. The results corroborated those of the primary analysis. The stricter criteria requiring EDSS less than 4.0 at baseline and relapse within 6 months of switching reduced the study sample. Again, the results of the primary analysis were confirmed. Finally, we stratified heDMT to either fingolimod or natalizumab. In both scenarios fingolimod and natalizumab were associated with superior control of relapse activity compared with the meDMT group, confirming the results of the primary analysis. It should be noted that the stratified analysis is not a comparison between fingolimod and natalizumab, as these two cohorts were not matched against each other. Accordingly, the low relapse rate ratio in the fingolimod analysis cannot be directly compared with the slightly higher relapse rate ratio from the natalizumab analysis.
Discussion
In this study, based on nationwide population-based registry data, we explored the effect of escalating therapy to an heDMT compared with switching to another meDMT in patients with RRMS who experienced disease breakthrough during treatment with an meDMT. The observed 28-35% relative reduction in relapse activity is of the same magnitude as the effect of meDMTs compared with placebo. On average, patients experienced 0.22 relapses per year on heDMT and 0.32 relapses per year on meDMT. Therapy escalation to heDMT was associated with increased time free of relapses compared with a switch to meDMT. The difference in hazard rate of 3-month confirmed EDSS worsening did not reach statistical significance, while the 3-month confirmed EDSS improvement analysis only just reached this threshold. The probability of switching between meDMTs was higher for patients originally treated with INFβ-1A Fig. 3 Kaplan Meier curves of time to the first relapse (a), time to the first 3-month confirmed EDSS worsening (b) and time to the first 3-month confirmed EDSS improvement (c) comparing patients who escalated therapy to a highly effective disease-modifying treatment (heDMT) with patients who switched to another moderately effective disease-modifying therapy (meDMT)
22 µg intramuscularly or INFβ-1B. This could be explained by the higher probability of developing neutralizing antibodies on INFβ-1B treatment [20, 21] , and because it was possible to switch to the higher dose of INFβ-1A (22 µg intramuscularly to 44 µg intramuscularly). Treatment strategies have become more complex over the years with the approval of several DMTs. When natalizumab became available, the option of a more effective therapy appeared. Even though fingolimod and natalizumab were shown to be more effective than IFNβ in the randomized controlled trials [11, 13, 15, 22] , they are used only as first-line therapy in patients with high disease activity at diagnosis [23] and as second-line therapy in patients treated with so-called first-line therapies who experience disease breakthrough. However, not all patients are escalated to an heDMT when experiencing disease breakthrough. In some countries, local regulations, regional availability of DMTs and reimbursement restrictions may be responsible for this, but even in countries with unrestricted drug availability, not all patients with disease breakthrough are escalated to an heDMT. A few small studies have reported that switching from one meDMT to another reduced ARR [18, 19, 24] . One study [18] showed a large decline in ARR from 1.23 to 0.53 in patients who switched due to clinical disease activity. This group of patients was not compared with a control group, suggesting that the large reduction in ARR probably represents the combined effect of treatment switch and regression to the mean. The two other studies showed ARRs between 0 and 0.25 after switching from one meDMT to another. A comparative study [25] found that patients with on-treatment clinical disease activity who switched to INFβ or GA had more relapses than those who escalated to fingolimod. Post-switch ARRs were 0.42 and 0.31 for the INFβ/GA treated group and the fingolimod treated group, respectively. Moreover, the HRs for first relapse and first disability worsening were 0.74 (95% CI 0.56-0.98) and 0.53 (95% CI 0.31-0.91) favoring fingolimod. A similar registerbased study [26] compared patients who switched from a first-line therapy to another first-line therapy with a group of patients who switched to natalizumab. The natalizumabtreated group did markedly better with an ARR of 0.20 compared with 0.58 in the control group. In addition, patients treated with natalizumab showed a reduced hazard rate of 3-month confirmed disability worsening (HR 0.74; 95% CI 0.55-0.74). Data from the Danish Multiple Sclerosis Registry have earlier been used to compare switching from a first-line therapy to either natalizumab or fingolimod. ARRs in this study were 0.296 and 0.307 for natalizumab and fingolimod, respectively [27] . Other studies have also investigated this issue [28, 29] . We did not show a statistically significant treatment effect in preventing disability worsening as was shown in the two mentioned comparison studies [25, 26] . Differences in study design and source population may explain the conflicting results. We included patients who had been treated with no more than one DMT before their therapy switch, resulting in inclusion of patients early in their disease course. It is well-known that worsening in EDSS in patients who are early in the disease course is relatively infrequent, irrespective of the treatment. Moreover, the comparative groups in our study were differently defined compared with the other studies as we included all INFβ, GA, teriflunomide and dimethyl fumarate in the meDMT group.
The ideal timepoint during a patient's disease course to start treatment with an DMT, to switch DMT or to stop DMT is difficult to predict [30] . A systematic review concluded that an early start of high-efficacy therapies has more potential in suppressing relapse activity [31] . It is important to escalate treatment in patients where switch to a more aggressive treatment will provide better disease control, but it is also important to avoid overtreating patients. The definition of disease breakthrough necessary for escalation has changed over time. Today, radiological disease breakthrough, defined as new lesions, newly enlarged lesions or GAD-enhancing T2 lesions, fulfill the criterion for escalation [32] . The strategy of switching due to MRI changes has evolved despite all pivotal RCTs required at least one clinical relapse within 12 months of start of follow-up. Accordingly, the guidelines recommending escalation to an heDMTs due to MRI worsening alone are not supported by strong evidence; nevertheless, escalation is still recommended in the ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis [32] and has become common practice. We defined disease breakthrough as the occurrence of a relapse within 12 months of the treatment switch constituting a modest disease activity. Despite this, we found a convincing effect on all relapse-related outcomes. Supportive of these results are the result of the sensitivity analysis requiring at least one relapse within 6 months of the treatment switch which also was convincing.
The limitations of our study are the potential bias due to unmeasured confounders, MRI data being the primary concern. However, data were collected in daily clinical practice and until recently only clinical disease breakthrough allowed escalation to heDMT. Another limitation is that the reason for switching versus escalating DMT could be systematically different in a way not captured by the propensity score. This risk was mitigated by the criterion that all patients experienced disease activity within 12 months of the change of DMT. Moreover, we tested whether requiring disease activity within 6 months of the change of DMT would change the study results. The results from these two analyses were Table 3 Primary and secondary outcomes in patients who after disease breakthrough on a moderately effective disease-modifying treatment (meDMT) escalated therapy to a highly effective disease-modifying treatment (heDMT) and patients who switched to another meDMT HR hazard ratio, CI confidence interval, meDMT moderately effective disease-modifying therapy, heDMT highly effective disease-modifying therapy similar, indicating that the 12-month definition in the main analyses was robust. In addition, if patients switched from one meDMT to another for reasons other than disease breakthrough and were misclassified and included in the meDMT group, bias would be expected to be towards less disease activity in the meDMT group. The main strength of our study is it being nationwide and population-based and that DMT is prescribed in only 14 public MS clinics. Selection bias in the source population is almost non-existent as DMT is free of charge, and the regulatory authorities require that data from all patients with MS treated with an DMT are prospectively registered in the Danish MS registry. This also improves the generalizability of our results. In addition, we conducted multiple sensitivity analyses supporting the main results.
In conclusion, our results support international treatment guidelines recommending escalation to heDMT in patients who experience disease breakthrough on a meDMT. Further, we agree with the recommendation that treatment with the entire spectrum of DMTs should be implemented in centers with adequate infrastructure to provide proper monitoring of patients and prompt and correct response to disease breakthrough.
